Author

Patricia P. Centeno

Cancer Research UK Manchester InstituteORCID 0000-0002-8754-7812Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Research Focus:cancer & tumor microenvironment· 2 Research Focus:cell type annotation· 2 Approach:experimental assay· 2 Organism:mouse· 2 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Approach:genetic perturbation / CRISPR· 1

Frequent Co-Authors

Andrew D. CampbelliD· 2 shared Catriona A. FordiD· 2 shared Owen James SansomiD· 2 shared Alison F. MunroiD· 1 shared Bryan SerrelsiD· 1 shared Christopher Chester· 1 shared Colin NixoniD· 1 shared Courtney BulliD· 1 shared

Activity by Year

2024-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 39 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Andrew D. CampbellORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologyNature CommunicationsPeer-reviewedJan 8, 2026

SOX2 empowers a rapid tumorigenic programme from the tumour resistant population in the skin

Patricia P. Centeno, Christopher Chester, Georgios Kanellos…·Owen James Sansom

This study identifies SOX2 as a key driver of rapid tumorigenesis from a previously resistant skin cell population in mice, with implications for human cutaneous squamous cell carcinoma.

5 citationstop 2%

mousebulk RNA-seq

𝕏 PostBluesky

Cancer BiologyCancer ResearchPeer-reviewedDec 5, 2024

A targetable PREX2/RAC1/PI3Kβ signalling axis confers resistance to clinically relevant therapeutic approaches in melanoma

Catriona A. Ford, Dana Koludrović, Patricia P. Centeno…·Andrew D. Campbell

This study identifies a druggable PREX2/RAC1/PI3Kβ signalling axis in BRAF-mutant melanoma that confers resistance to therapies and can be targeted to improve treatment outcomes.

8 citations

mousehuman

𝕏 PostBluesky